. Author manuscript; available in PMC: 2016 Apr 1.

Published in final edited form as: Clin Microbiol Infect. 2014 Nov 23;21(4):387.e5–387.e8. doi: 10.1016/j.cmi.2014.11.012

TABLE 1.

Demographic, clinical and laboratory characteristics of the HBsAg-positive patients with paired cerebrospinal fluid–plasma samples

No. of patients		26
Gender	M/F	15/11
Age at diagnosis of HIV-infection (years)	Median (limits)	10 (1–20)
Age at diagnosis of neurological complication (years)	Mean ± SD	17.0 ± 2.12
HIV-1 transmission route	Parenteral (non-IDU)	25
	Vertical	1
CD4 count (lf/mm³)	Median (range)	164 (1–738)
Mean HIV RNA ± SD (log₁₀ copies/mL)	Plasma	3.86 ± 1.40
	CSF	3.07 ± 1.18
History of exposure to ART		20
History of exposure to 3TC		18
On ART containing 3TC before the neurological complication		15
HBV markers	HBeAg positive	13 of 22 tested
	HDV antibodies positive	4 of 20 tested
	HBV DNA plasma (IU/mL) mean ± SD	4.7 ± 2.63^***
	HBV DNA CSF (IU/mL) mean ± SD	2.74 ± 1.33^***
Positive HBV DNA (>60 IU/mL)	Plasma	18 patients
	CSF	11 patients
HBV DNA log₁₀ IU/mL in patients exposed to 3TC before lumbar puncture (n = 15)	Mean Plasma values	3.57 ± 2.10^**
	Mean CSF values	2.16 ± 0.92^*
HBV DNA log₁₀ IU/mL in patients not exposed to 3TC before lumbar puncture (n = 11)	Mean Plasma values	6.26 ± 2.55^**
	Mean CSF values	3.54 ± 1.42^*

p < 0.01;

^**

p 0,007;

^***

p 0.0001.

Abbreviations: 3TC, lamivudine; ART, antiretroviral treatment; CSF, cerebrospinal fluid; HbeAg, hepatitis B e antigen; HBV, hepatitis B virus; HDV, hepatitis D virus; HIV, human immunodeficiency virus; IDU, intravenous drug user.